In ER+ breast cancer, resistance to drugs like tamoxifen is regulated by the EMT-associated factors ZEB1, miR-200, and SLUG, as they interact with the estrogen receptor alpha (ERα). This evidence concerns the gene ESR1 and breast cancer.